Table 1 The principal characteristics and further details of eligible articles
Author | Year | Study design | Region | Number of patient | Male | Median age (IQR) (years) | Diagnosis method for COVID-19 | Cancer type | Comparison group | |||
Kuderer NM [6] | 2020 | Retro-prospective | multi-national | 928 | 468 | 66 (57–76) | RT-PCR | non-specific | cancer patients with no treatment | |||
Lee LYW [19] | 2020 | Prospective | UK | 800 | 449 | 69 (59–76) | RT-PCR | non-specific | cancer patients with no treatment | |||
Zhang L [14] | 2020 | Retrospective | China | 28 | 17 | 65 (56–70) | RT-PCR | solid tumor | cancer patients with no treatment | |||
Stroppa EM [20] | 2020 | Retrospective | Italy | 25 | 20 | 71 (mean) (50–84) | RT-PCR | non-specific | cancer patients with no treatment | |||
Yang K [7] | 2020 | Retrospective | China | 205 | 96 | 63 (56–70) | RT-PCR | non-specific | cancer patients with no treatment | |||
Zhang H [21] | 2020 | Retrospective | China | 107 | 60 | 66 (36–98) | RT-PCR and/or radiology | non-specific | cancer patients with no treatment | |||
Robilotti EV [22] | 2020 | Retrospective | USA | 423 | 212 | NA | RT-PCR | non-specific | cancer patients with no treatment | |||
Yarza R [23] | 2020 | Prospective | Spain | 63 | 34 | NA | RT-PCR and/or radiology | solid tumor | cancer patients treated other options | |||
Li Q [24] | 2020 | Retrospective | China | 59 | 31 | 63 (54–70) | RT-PCR | non-specific | cancer patients with no treatment | |||
Jee J [25] | 2020 | Retrospective | USA | 309 | 159 | NA | RT-PCR | non-specific | cancer patients with no treatment | |||
Sanchez-Pina JM [26] | 2020 | Retrospective | Spain | 39 | 23 | 64 (mean) | RT-PCR | hematological malignancies | cancer patients with no treatment | |||
Pinato DJ [15] | 2020 | Retrospective | multi-national | 890 | 503 | 68 (mean) | RT-PCR | non-specific | cancer patients with no treatment | |||
Assaad S [27] | 2020 | Retrospective | France | 55 | 26 | 64 (mean) | RT-PCR | non-specific | cancer patients with no treatment | |||
Garassino MC [28] | 2020 | Retrospective | multi-national | 200 | 141 | 68 (61–75) | RT-PCR | Thoracic Cancer | cancer patients with no treatment | |||
Liang WH [29] | 2020 | Retrospective | China | 18 | 12 | 60 (47–87) | RT-PCR | non-specific | cancer patients with no treatment | |||
Ma J [30] | 2020 | Retrospective | China | 37 | 20 | 62 (IQR: 59–70) | RT-PCR and/or antibody test | solid tumor | cancer patients with no treatment | |||
Mehta V [11] | 2020 | Retrospective | USA | 218 | 127 | 69 (10–92) | RT-PCR | non-specific | cancer patients with no treatment | |||
Yu J [31] | 2020 | Retrospective | China | 12 | 10 | 66 (48–78) | RT-PCR and/or CT | solid tumor | cancer patients with no active antitumor treatment | |||
Tian J [4] | 2020 | Retrospective | China | 232 | 119 | 64 (58–69) | RT-PCR | non-specific | cancer patients with surgery | |||
Fox TA [32] | 2020 | Retrospective | UK | 55 | 38 | 63 (23–88) | RT-PCR, CT, and clinical features | hematological malignancies | cancer patients with no treatment | |||
Booth S [33] | 2020 | Prospective | UK | 66 | 41 | 73 (IQR: 63–81) | RT-PCR, radiological, and clinical features | hematological malignancies | cancer patients with no treatment | |||
Cattaneo C [34] | 2020 | Retrospective | Italy | 102 | 66 | 68 (mean) | RT-PCR | hematological malignancies | cancer patients with no treatment | |||
Lara OD [35] | 2020 | Retrospective | USA | 121 | NA | 64 (IQR: 51–73) | RT-PCR and CT | gynecologic cancer | cancer patients with no treatment | |||
Liu C [36] | 2020 | Retrospective | China | 216 | 113 | 63 (IQR: 57–70) | RT-PCR | solid tumor | cancer patients with no treatment | |||
Luo J [37] | 2020 | Retrospective | USA | 102 | 49 | 68 (IQR: 61–75) | RT-PCR | lung cancer | cancer patients with no treatment | |||
Mato AR [38] | 2020 | Retrospective | multi-national | 198 | 125 | 63 (35–92) | RT-PCR | chronic lymphocytic leukemia | cancer patients with no treatment | |||
Rogado J [39] | 2020 | Retrospective | Spain | 45 | 30 | 71 (34–90) | RT-PCR | non-specific | cancer patients with no treatment | |||
Russell B [40] | 2020 | Retro-prospective | UK | 156 | 90 | 65 (mean) | RT-PCR | solid tumor | cancer patients with no treatment | |||
Scarfò L [41] | 2020 | Retrospective | multi-national | 190 | 126 | 72 (48–94) | RT-PCR | chronic lymphocytic leukemia | cancer patients with no treatment | |||
Vuagnat P [42] | 2020 | Retrospective | France | 58 | NA | 58 (IQR:48–68) | RT-PCR and/or CT | breast cancer | cancer patients with no treatment | |||
Wang BO [43] | 2020 | Retrospective | USA | 58 | 30 | 67 | RT-PCR | multiple myeloma | cancer patients with no treatment | |||
Wang J [44] | 2020 | Retrospective | China | 283 | 141 | 63 (IQR: 55–70) | RT-PCR | non-specific | cancer patients with no treatment | |||
Gonzalez-cao M [45] | 2020 | Retrospective | Spain | 50 | 27 | 69 (6–94) | clinical or RT-PCR | melanoma | cancer patients with no treatment | |||
De Melo AC [46] | 2020 | Retrospective | Brazil | 181 | 71 | 55 (2–88) | RT-PCR | non-specific | cancer patients with no active antitumor treatment | |||
Albiges L [47] | 2020 | Retrospective | France | 178 | 76 | 61 (52–71) | RT-PCR and/or CT | non-specific | cancer patients with no treatment | |||
MartÃnez-López J [48] | 2020 | Retrospective | Spain | 167 | 95 | 71 (IQR: 62–78) | RT-PCR | multiple myeloma (MM) | cancer patients with no treatment | |||
MartÃn-Moro F [49] | 2020 | Retrospective | Spain | 34 | 19 | 72.5 (35–94) | RT-PCR and/or CT | hematological malignancies | cancer patients with no treatment | |||
Lattenist R [50] | 2021 | Retrospective | Belgium | 13 | 10 | 70 (IQR: 59–79) | RT-PCR and/or CT | hematological malignancies | cancer patients with no treatment | |||
Nakamura S [51] | 2020 | Retrospective | Japan | 32 | 22 | 74.5 (24–90) | RT-PCR | non-specific | cancer patients with no treatment | |||
Rogiers A [52] | 2021 | Retrospective | multi-national | 110 | 72 | 63 (27–86) | RT-PCR | non-specific | cancer patients with no treatment | |||
Glenthøj A [16] | 2021 | Prospective | Denmark | 66 | 40 | 66.7 (25–91) |  | hematological malignancies | cancer patients with no treatment | |||
Song C [17] | 2020 | Retrospective | China | 223 | 116 | 63 (56–71) | RT-PCR | non-specific | cancer patients with discontinous treatment | |||
Lunski MJ [18] | 2020 | Retrospective | USA | 312 | 142 | NA | RT-PCR | non-specific | cancer patients with no treatment | |||
Nie L [53] | 2020 | Retrospective | China | 45 | 31 | 66 (58–74) | RT-PCR | lung cancer | cancer patients with no treatment | |||
Larfors G [54] | 2020 | Retrospective | Sweden | NA | NA | NA | RT-PCR | non-specific | cancer patients with no treatment | |||
H€ollein A [55] | 2020 | Retrospective | Germany | 17 | 8 | 73 (27–82) | RT-PCR | non-specific | cancer patients with no treatment | |||
Garnett C [56] | 2020 | Retrospective | UK | 32 | 21 | 72.5 (46–96) | RT-PCR | hematological malignancies | cancer patients with no treatment | |||
Hanna GJ [57] | 2020 | Retrospective | USA | 32 | 20 | 70 (38–91) | RT-PCR | head and neck cancer | cancer patients with no treatment | |||
Lie’vre A [58] | 2020 | Retro-prospective | France | 1289 | 795 | 67 (19–100) | RT-PCR | solid tumor | cancer patients with no treatment | |||
Smith M [59] | 2020 | Retrospective | USA | 86 | NA | 69 (mean) | RT-PCR | solid tumor | cancer patients with no treatment | |||
Wu YG [60] | 2020 | Retrospective | China | 14 | 9 | 37 (14–68) | RT-PCR | hematological malignancies | cancer patients with no treatment | |||
Yang F [12] | 2020 | Retrospective | China | 52 | 28 | 63 (34–98) | RT-PCR | solid tumor | cancer patients with no treatment | |||
Author | Number of the control | Anti-tumor therapy | Chemotherapy | Immunotherapy | Targeted therapy | Endocrine therapy | Surgery | Radiotherapy | Outcome | Required mechanical ventilation | Severe COVID-19 | Death |
Kuderer NM [6] | 553 | 366 | 160 | 38 | 75 | 85 | 32 | 12 | death | 116 | 242 | 121 |
Lee LYW [19] | 272 | 528 | 281 | 44 | 72 | 64 | 29 | 76 | death | NA | 360 | 226 |
Zhang L [14] | 22 | 6 | 3 | 1 | 2 | NA | NA | 1 | sever COVID-19 | 10 | 15 | 8 |
Stroppa EM [20] | 13 | 12 | 8 | 4 | NA | NA | NA | NA | death | NA | NA | 9 |
Yang K [7] | 128 | 54 | 31 | 4 | 12 | NA | 4 | 9 | death | 32 | 52 | 40 |
Zhang H [21] | 70 | 37 | NA | 6 | NA | NA | NA | NA | death | NA | 56 | 23 |
Robilotti EV [22] | NA | NA | 191 | 31 | NA | NA | 31 | NA | sever COVID-19 | 40 | 85 | 51 |
Yarza R [23] | NA | NA | 36 | 8 | 7 | 10 | NA | NA | sever COVID-19; death | NA | 24 | 16 |
Li Q [24] | 43 | 16 | 12 | NA | 6 | NA | 1 | 1 | death | 27 | 35 | 16 |
Jee J [25] | 43 | 170 | 102 | 18 | 49 | NA | NA | NA | sever COVID-19 | NA | 120 | 31 |
Sanchez-Pina JM [26] | 15 | 24 | 4 | NA | 5 | NA | NA | NA | death | NA | 18 | NA |
Pinato DJ [15] | 403 | 479 | 206 | 56 | 93 | 92 | NA | 33 | sever COVID-19; death | 97 | 565 | 299 |
Assaad S [27] | 26 | 29 | 16 | 3 | 14 | NA | NA | NA | death | NA | NA | 30 |
Garassino MC [28] | 58 | 142 | 48 | 34 | 28 | NA | NA | NA | death | 9 | NA | 66 |
Liang WH [29] | 14 | 4 | NA | NA | NA | NA | NA | NA | sever COVID-19 | NA | 9 | NA |
Ma J [30] | 24 | 13 | NA | NA | NA | NA | NA | NA | sever COVID-19 | NA | 20 | 5 |
Mehta V [11] | NA | NA | 42 | 5 | NA | NA | NA | 49 | death | 45 | NA | 61 |
Yu J [31] | 5 | 7 | 5 | 2 | 1 | NA | 1 | 4 | sever COVID-19; death | NA | 3 | 3 |
Tian J [4] | NA | NA | NA | NA | NA | NA | 119 | NA | sever COVID-19 | NA | 148 | NA |
Fox TA [32] | NA | NA | 29 | 25 | NA | NA | NA | NA | sever COVID-19; death | NA | 25 | 19 |
Booth S [33] | 29 | 37 | NA | NA | NA | NA | NA | NA | death | NA | NA | 34 |
Cattaneo C [34] | 43 | 59 | 20 | 28 | NA | NA | NA | NA | death | NA | NA | 40 |
Lara OD [35] | NA | NA | NA | NA | NA | NA | NA | NA | death | NA | 20 | NA |
Liu C [36] | 138 | 78 | NA | NA | NA | NA | NA | NA | death | NA | NA | 37 |
Luo J [37] | 48 | 54 | NA | NA | NA | NA | NA | NA | sever COVID-19; death | 18 | NA | 25 |
Mato AR [38] | 79 | 119 | 51 | NA | NA | NA | NA | NA | death | 53 | NA | 66 |
Rogado J [39] | 15 | 30 | 19 | 1 | 2 | NA | NA | NA | death | NA | 29 | 19 |
Russell B [40] | 18 | 81 | 45 | 7 | 5 | NA | NA | NA | sever COVID-19; death | NA | 28 | 34 |
Scarfò L [41] | 73 | 116 | NA | NA | NA | NA | NA | NA | sever COVID-19; death | NA | 151 | 56 |
Vuagnat P [42] | NA | NA | 29 | NA | 19 | 19 | 3 | 36 | sever COVID-19 | NA | NA | 4 |
Wang BO [43] | 11 | 47 | NA | NA | 28 | NA | NA | NA | death | NA | NA | 14 |
Wang J [44] | 188 | 95 | 46 | NA | 12 | NA | 23 | NA | sever COVID-19; death | NA | NA | 50 |
Gonzalez-cao M [45] | 12 | 38 | NA | 22 | 16 | NA | NA | NA | sever COVID-19; death | NA | 34 | 13 |
De Melo AC [46] | 16 | 165 | 63 | NA | NA | 20 | 12 | 10 | death | 34 | NA | 60 |
Albiges L [47] | 61 | 117 | 66 | 19 | 30 | 16 | NA | NA | sever COVID-19; death | NA | 47 | 31 |
MartÃnez-López J [48] | NA | NA | 83 | NA | NA | NA | NA | NA | death | 15 | 141 | 56 |
MartÃn-Moro F [49] | NA | 19 | NA | NA | NA | NA | NA | NA | death | 4 | 17 | 11 |
Lattenist R [50] | 6 | 7 | 3 | NA | NA | NA | NA | NA | death | NA | NA | 6 |
Nakamura S [51] | 19 | 13 | 10 | 3 | NA | 4 | 13 | NA | death | 3 | NA | 11 |
Rogiers A [52] | NA | NA | 25 | NA | NA | NA | NA | NA | sever COVID-19; death | NA | 35 | 18 |
Glenthøj A [16] | 10 | 9 | NA | NA | NA | NA | NA | NA | sever COVID-19 | NA | 33 | NA |
Song C [17] | 19 | 204 | NA | NA | NA | NA | NA | NA | sever COVID-19 | NA | 159 | NA |
Lunski MJ [18] | 256 | 56 | 12 | 4 | 9 | 44 | 5 | 2 | death | NA | NA | 66 |
Nie L [53] | 34 | 11 | 4 | 4 | NA | NA | 3 | NA | death | 3 | 23 | 11 |
Larfors G [54] | NA | NA | NA | NA | NA | NA | NA | NA | sever COVID-19; death | NA | NA | NA |
H€ollein A [55] | 2 | 15 | 14 | 1 | 2 | NA | NA | 1 | death | 3 | NA | 6 |
Garnett C [56] | 10 | 22 | NA | NA | NA | NA | NA | NA | death | NA | NA | 18 |
Hanna GJ [57] | 26 | 6 | 3 | 1 | 0 | NA | 4 | 1 | death | NA | NA | NA |
Lie’vre A [58] | NA | NA | 577 | 110 | 181 | 57 | 56 | 133 | death | 49 | NA | 370 |
Smith M [59] | 47 | 39 | NA | NA | NA | NA | NA | NA | sever COVID-19 | NA | 29 | NA |
Wu YG [60] | NA | NA | 7 | NA | NA | NA | NA | NA | death | NA | NA | 6 |
Yang F [12] | NA | NA | 6 | 1 | NA | NA | 2 | NA | sever COVID-19 | NA | 19 | 11 |